Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models

Journal of Neuro-Oncology

Volumn 116, Issue 3, 2014, Pages 523-531

  Cao, Lei ^a   Gao, Hua ^a   Gui, Songbai ^a   Bai, Giwei ^a   Lu, Runchun ^a   Wang, Fei ^a   Zhang, Yazhuo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

catenin; Estrogen receptor ; Fulvestrant; Prolactinoma; Wnt signaling pathway

Indexed keywords

ANIMALS; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALEIMIDES; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RATS; RATS, INBRED F344; TIME FACTORS;

EID: 84894082754     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1351-8     Document Type: Review

References (24)

1. Colao A, Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352:1455-1461
2. Serri O, Noiseux D, Robert F, Hardy J (1996) Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. J Clin Endocrinol Metab 81:3177-3179
3. Lloyd RV (1983) Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. Am J Pathol 113:198-206
4. Ergote I, Abram P (2006) Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 17:200-204
5. Lv H, Li C, Gui S, Sun M, Li D, Zhang Y (2011) Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line. J Neurooncol 102:237-245
6. Willert K, Jones KA (2006) Wnt signaling: is the party in the nucleus? Genes Dev 20:1394-1404
7. Giles RH, van Es JH, Clevers H (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653:1-24
8. Varea O, Garrido JJ, Dopazo A, Mendez P, Garcia-Segura LM, Wandosell F (2009) Estradiol activates beta-catenin dependent transcription in neurons. PLoS ONE 4:e5153
9. Bai J, Gui S, Zhang Y (2013) Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine- resistant prolactinomas. J Clin Neurosci 20:721-725
10. Giles A, MadecF Friedrichsen S, Featherstone K, Chambers T, Harper CV, Resch J, Brabant G, Davis JR (2011) Wnt signaling in estrogen-induced lactotroph proliferation. J Cell Sci 124:540-547
11. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R (2003) Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146-150
12. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485-534
13. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N (2005) Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 239:27-36
14. Li C, Sun Z, Gui S, Liu F, Zhang Y (2009) Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism. Neuro Endocrinol Lett 30:268-274
15. Leng L, Zhang Y (2011) Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line. J Clin Neurosci 18:1694-1698
16. Wijayaratne AL, McDonnell DP (2001) The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276:35684-35692
17. Wardell SE, Marks JR, McDonnell DP (2011) The turnover of estrogen receptor a by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biocheml Pharmacol 82:122-130
18. Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388
19. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC (2005) Interaction of nuclear receptors with the Wnt/β-Catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 26:898-915
20. Semba S, Han SY, Ikeda H, Horii A (2001) Frequent nuclear accumulation of beta-catenin in pituitary adenoma. Cancer 91:42-48
21. Varea O, Arevalo MA, Garrido JJ, Garcia-Segura LM, Wandosell F, Mendez P (2010) Interaction of estrogen receptors with insulin-like growth factor-I and Wnt signaling in the nervous system. Steroids 75:565-569
22. Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD (2006) Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27:1341-1348
23. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson BG, McDonald KL (2008) Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinol 149:1235-1242
24. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054